- Home
- CPOP vs NERV Comparison
CPOP vs NERV Comparison
Compare CPOP & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CPOP
- NERV
- Stock Information
- Founded
- CPOP 2007
- NERV 2007
- Country
- CPOP China
- NERV United States
- Employees
- CPOP N/A
- NERV N/A
- Industry
- CPOP Services-Misc. Amusement & Recreation
- NERV Biotechnology: Pharmaceutical Preparations
- Sector
- CPOP Consumer Discretionary
- NERV Health Care
- Exchange
- CPOP Nasdaq
- NERV Nasdaq
- Market Cap
- CPOP 17.9M
- NERV 18.3M
- IPO Year
- CPOP 2021
- NERV 2014
- Fundamental
- Price
- CPOP $1.14
- NERV $2.29
- Analyst Decision
- CPOP
- NERV Hold
- Analyst Count
- CPOP 0
- NERV 1
- Target Price
- CPOP N/A
- NERV $5.00
- AVG Volume (30 Days)
- CPOP 101.1K
- NERV 24.1K
- Earning Date
- CPOP 12-06-2024
- NERV 11-05-2024
- Dividend Yield
- CPOP N/A
- NERV N/A
- EPS Growth
- CPOP N/A
- NERV N/A
- EPS
- CPOP N/A
- NERV N/A
- Revenue
- CPOP $47,381,918.00
- NERV N/A
- Revenue This Year
- CPOP N/A
- NERV N/A
- Revenue Next Year
- CPOP N/A
- NERV N/A
- P/E Ratio
- CPOP N/A
- NERV N/A
- Revenue Growth
- CPOP 155.52
- NERV N/A
- 52 Week Low
- CPOP $0.91
- NERV $2.07
- 52 Week High
- CPOP $9.67
- NERV $13.49
- Technical
- Relative Strength Index (RSI)
- CPOP 42.01
- NERV 45.73
- Support Level
- CPOP $1.18
- NERV $2.08
- Resistance Level
- CPOP $1.45
- NERV $2.35
- Average True Range (ATR)
- CPOP 0.08
- NERV 0.11
- MACD
- CPOP -0.01
- NERV 0.00
- Stochastic Oscillator
- CPOP 3.17
- NERV 56.27
About CPOP Pop Culture Group Co. Ltd
Pop Culture Group Co Ltd hosts entertainment events, operates hip-hop-related online programs, and provides event planning and execution services and marketing services to corporate clients. It generates revenue from our Event Hosting business by providing sponsorship packages to advertisers in exchange for sponsorship fees and by selling tickets for those concerts.
About NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.